BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32405972)

  • 1. CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome.
    Perera Y; Ramos Y; Padrón G; Caballero E; Guirola O; Caligiuri LG; Lorenzo N; Gottardo F; Farina HG; Filhol O; Cochet C; Perea SE
    Mol Cell Biochem; 2020 Jul; 470(1-2):63-75. PubMed ID: 32405972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
    Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
    Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.
    Perera Y; Farina HG; Gil J; Rodriguez A; Benavent F; Castellanos L; Gómez RE; Acevedo BE; Alonso DF; Perea SE
    Mol Cancer Ther; 2009 May; 8(5):1189-96. PubMed ID: 19417160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
    Perea SE; Reyes O; Baladron I; Perera Y; Farina H; Gil J; Rodriguez A; Bacardi D; Marcelo JL; Cosme K; Cruz M; Valenzuela C; López-Saura PA; Puchades Y; Serrano JM; Mendoza O; Castellanos L; Sanchez A; Betancourt L; Besada V; Silva R; López E; Falcón V; Hernández I; Solares M; Santana A; Díaz A; Ramos T; López C; Ariosa J; González LJ; Garay H; Gómez D; Gómez R; Alonso DF; Sigman H; Herrera L; Acevedo B
    Mol Cell Biochem; 2008 Sep; 316(1-2):163-7. PubMed ID: 18575815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
    Perea SE; Baladrón I; Valenzuela C; Perera Y
    Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.
    Gottardo MF; Capobianco CS; Sidabra JE; Garona J; Perera Y; Perea SE; Alonso DF; Farina HG
    Sci Rep; 2020 Sep; 10(1):14689. PubMed ID: 32895446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kinesin I family member KIF5C is a novel substrate for protein kinase CK2.
    Schäfer B; Götz C; Montenarh M
    Biochem Biophys Res Commun; 2008 Oct; 375(2):179-83. PubMed ID: 18682247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells.
    Rodríguez-Ulloa A; Ramos Y; Gil J; Perera Y; Castellanos-Serra L; García Y; Betancourt L; Besada V; González LJ; Fernández-de-Cossio J; Sanchez A; Serrano JM; Farina H; Alonso DF; Acevedo BE; Padrón G; Musacchio A; Perea SE
    J Proteome Res; 2010 Oct; 9(10):5473-83. PubMed ID: 20804217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
    Perea SE; Baladron I; Garcia Y; Perera Y; Lopez A; Soriano JL; Batista N; Palau A; Hernández I; Farina H; Garcia I; Gonzalez L; Gil J; Rodriguez A; Solares M; Santana A; Cruz M; Lopez M; Valenzuela C; Reyes O; López-Saura PA; González CA; Diaz A; Castellanos L; Sanchez A; Betancourt L; Besada V; González LJ; Garay H; Gómez R; Gómez DE; Alonso DF; Perrin P; Renualt JY; Sigman H; Herrera L; Acevedo B
    Mol Cell Biochem; 2011 Oct; 356(1-2):45-50. PubMed ID: 21735096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
    Bollacke A; Nienberg C; Borgne ML; Jose J
    J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CK2 kinase activity but not its binding to CK2 promoter regions is implicated in the regulation of CK2α and CK2β gene expressions.
    Lupp S; Gumhold C; Ampofo E; Montenarh M; Rother K
    Mol Cell Biochem; 2013 Dec; 384(1-2):71-82. PubMed ID: 23963994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model.
    Pérez GV; Rosales M; Ramón AC; Rodríguez-Ulloa A; Besada V; González LJ; Aguilar D; Vázquez-Blomquist D; Falcón V; Caballero E; Carvalho PC; Caldeira RS; Yang K; Perera Y; Perea SE
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.
    Perera Y; Costales HC; Diaz Y; Reyes O; Farina HG; Mendez L; Gómez RE; Acevedo BE; Gomez DE; Alonso DF; Perea SE
    J Pept Sci; 2012 Apr; 18(4):215-23. PubMed ID: 22407768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activity of CK2 in the extracts of COS-7 cells transfected with wild type and mutant subunits of protein kinase CK2.
    Korn I; Jacob G; Allende CC; Allende JE
    Mol Cell Biochem; 2001 Nov; 227(1-2):37-44. PubMed ID: 11827173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand.
    Raaf J; Guerra B; Neundorf I; Bopp B; Issinger OG; Jose J; Pietsch M; Niefind K
    ACS Chem Biol; 2013 May; 8(5):901-7. PubMed ID: 23474121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
    Rosales M; Pérez GV; Ramón AC; Cruz Y; Rodríguez-Ulloa A; Besada V; Ramos Y; Vázquez-Blomquist D; Caballero E; Aguilar D; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
    Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual effect of lysine-rich polypeptides on the activity of protein kinase CK2.
    Romero-Oliva F; Jacob G; Allende JE
    J Cell Biochem; 2003 May; 89(2):348-55. PubMed ID: 12704797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.
    Garay H; Espinosa LA; Perera Y; Sánchez A; Diago D; Perea SE; Besada V; Reyes O; González LJ
    J Pept Sci; 2018 Jun; 24(6):e3081. PubMed ID: 29676523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects.
    Zanin S; Sandre M; Cozza G; Ottaviani D; Marin O; Pinna LA; Ruzzene M
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1694-707. PubMed ID: 25936516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential localization of alpha' and beta subunits of protein kinase CK2 during rat spermatogenesis.
    Alvarado-Díaz CP; Tapia JC; Antonelli M; Moreno RD
    Cell Tissue Res; 2009 Oct; 338(1):139-49. PubMed ID: 19711102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.